DB15852ExperimentalVaccines
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure... VLPs are thought to have multiple mechanisms involving the immune system which engage both humoral and cellular responses.
- Code names
- Coronavirus-Like Particle COVID-19 Vaccine
What you can answer from here — as of May 11, 2026
Which companies are running trials of Coronavirus-Like Particle COVID-19 Vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account